Q1 2026 Earnings Call Transcript June 6, 2025 Operator: Good afternoon, ladies and gentlemen. Thank you for joining ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

The company completed a strategic transaction with United Trademark Group in April 2025, providing $3 million in liquidity ...

Growth continues in military and specialty markets; data center revenues are present in Tier 2 and Tier 3 segments but remain ...

Q1 2025 Earnings Call Transcript June 5, 2025 Hello Group Inc. beats earnings expectations. Reported EPS is $2.34, ...

EngageLab Contract Value: 63 million RMB newly signed in Q1 2025, bringing the total cumulative contract value to over 110 ...

Netflix ( NFLX 1.83%) just keeps winning. Through the first five months of 2025, the global media empire has seen its shares ...

Phoenix Motor Inc (PEVM) reports a remarkable 900% revenue increase and strategic growth, despite operational challenges and Nasdaq listing delays.

Palantir's Q1 2025 results confirm strong growth, rising margins, and scaling AI adoption. Find out why PLTR stock is a Buy.

Organogenesis' Q1 2025 earnings disappointed, with dominant Advanced Wound Care segment experiencing a sharp revenue decline ...

Palantir's growth story is intact despite challenges. Read more on PLTR's Q1 highlights, strong US commercial momentum, and ...